At the forefront of therapies for rare and orphan diseasesTM
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events

Home >> Investor Relations >> Investor Relations

Investor Relations

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

View all »Recent Releases

Feb 10, 2016
Amicus Therapeutics Announces Presentations and Posters at 12th Annual WORLDSymposium™ 2016  

Feb 9, 2016
Amicus Therapeutics Strengthens Executive Leadership Team

View all »Events & Presentations

Feb 10, 2016
LEERINK Partners 5th Annual Global Healthcare Conference

Jan 12, 2016 at 9:00 AM PT
34th Annual J.P. Morgan Healthcare Conference

Copyright © 2016 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy